“By unlocking these areas of research and development, these new markets will create new opportunities for investors and inspire new thoughts for entrepreneurs.”

Kevin Xu is the CEO of MEBO International and Skingenix, specializing in human body regeneration science and the development of its applications. He also founded MEBO Campus, a virtual education platform for organ regeneration science. In addition to his entrepreneurial endeavors, Kevin is an appointee of the California-China Advisory Group and the founder of the Regeneration X Foundation, a nonprofit organization providing support for the establishment of in-situ regenerative life science education systems and research collaboration.

Businessinterviews.com: Tell us a little about Skingenix. What are your goals, and what makes this endeavor unique?

Kevin: Skingenix is the only company in the U.S. authorized to use human body regenerative restoration science to develop a drug to regenerate damaged organs. My father, Dr. Rongxiang Xu, is the inventor of human organ regeneration science, and our mission is to translate his vision into standardized applications in the U.S.

Currently, Skingenix is focusing on the external organ branch of this area of research, developing organ in-situ regenerative products for improving human health and quality of life. With more than 20 years of clinical experience in science worldwide, we’re able to provide the highest quality standards, which ensure safety and efficacy to deliver our research in the U.S.

Businessinterviews.com: Your applied research recently completed phase two of FDA trials. Tell us why this milestone is so important.

Kevin: Our investigational product is now entering phase three of drug development after completing a phase-two randomized and controlled multicenter clinical study to assess the safety and efficacy for patients with diabetic foot ulcers.

Our research is based on a multiple-ingredient botanical regenerative nutrient, which activates potential regenerative cells in the human body to perform organ regeneration. This field of science has developed a unique path in the life science industry because it opens up multiple new markets that were previously locked up — including the multiple-ingredient botanical and in-situ organ regeneration markets.

By unlocking these areas of research and development, these new markets will create new opportunities for investors and inspire new thoughts for entrepreneurs.

Currently, the FDA doesn’t have fully established industry guidelines for multiple-ingredient botanical drugs. But by following our research through phase-three approval, we’re working with the FDA to produce the standardization of chemistry, manufacturing, and control (the set of processes in preclinical drug development) to ensure the quality and control of raw materials and manufacturing.

We’re working to provide exemplary guidance for others in this industry so they can follow suit.

Businessinterviews.com: What are some of the regulatory hurdles you face?

Kevin: The biggest challenge I foresee is not so much related to regulatory issues, but rather social impacts. For example, if people have the opportunity to benefit from a technology they’ve only seen depicted in stories set hundreds of years from now, will they be ready to accept it today?

Our research is under the category of applied science rather than mechanism science, which emphasizes its value for real-world application. The biggest questions are: How long will it take people to fully adopt this instant realization of a futuristic science? How long will it take to understand the ideology of this work? And how long will it take for people to truly understand the gap between concept and application in science?

To me, the best approach to understanding this research is not through learning, but through application and use.

Businessinterviews.com: Skingenix is a unique company. How does this model affect your management style?

Kevin: I like to compare leading Skingenix to conducting an orchestra.

My job focuses on conducting multi-center clinical trials while simultaneously ensuring the quality control of the manufacturing of the drug we’re researching. As CEO, I expect two specific characteristics from my employees: being functionally driven and able to multitask.

In terms of being functionally driven, the productivity of each employee requires my ability to assess their needs for training and their function within the team. At Skingenix, we train employees for multiple positions, so if someone is absent, we’re still able to function and continue our work.

When I say multitasking, I mean management rather than task execution. Multitask management means that managers monitor employees who may not have the same expertise as they do to help them reach their goals and move the company forward.

For example, our clinical trial director reports to the executive director and the CMC director so everyone is synchronized and keeps pace. The executive director may not have the same skills or background as the clinician, but he’s able to observe reachable goals and hold the whole team accountable.

Businessinterviews.com: You became the CEO of Skingenix at a very young age. How do you think this has hindered or helped you as a strategist and an entrepreneur?

Kevin: Becoming CEO as a young person was somewhat of a hindrance — especially in the biotech field — and it required a lot of fast learning and risk-taking.

However, I also believe that being a young CEO helped my mental state. I had less fear when facing stressful situations and more determination when making decisions. As a young entrepreneur, I’m also more open-minded to accept change and consider new opportunities.

Businessinterviews.com: What advice do you have for other young entrepreneurs looking to develop startups in the life sciences industry?

Kevin: You must have an indestructible faith in the research idea you’re working to develop. That’s the one and only piece of advice I have for them. It’s like a marriage. Once you make the full commitment to your partner, you’ll devote everything you have and trust her without any hesitation or skepticism.

Businessinterviews.com: What’s next for Skingenix?

Kevin: After we finish the phase-three trial of our investigative product, we’ll receive approval from the FDA, which will enable us to expand the portfolio of our company pipeline. Currently, the science has turned into different applications and is saving lives in more than 70 countries. My duty is to make sure we’re able to unleash the full potential of the research in the U.S.

The concept of the research is very simple to understand. People are innately born with potentially regenerative cells in their bodies. Once these PRCs are awakened by the nutrient, it will initiate in-situ organ regeneration (your body’s ability to restore physiologically).

Therefore, any type of external organ can actually follow the same route to regenerate, so the number of indications for research is hard to estimate.

We hope to continue developing trials around external organs, and once we’re ready, we’ll move on to internal organs such as the heart and lungs. My vision for the future is the incoming era of organ regeneration medicine, which means people will have better treatment available and will be able to survive traumatic injuries.